{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:26:42Z","timestamp":1774358802249,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL069749"],"award-info":[{"award-number":["5T32HL069749"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019365","name":"CryoLife","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ahj.2020.06.014","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T11:25:38Z","timestamp":1593084338000},"page":"91-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve"],"prefix":"10.1016","volume":"227","author":[{"given":"Oliver K.","family":"Jawitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittanny","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwasoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Anstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Blackstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod H.","family":"Thourani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Puskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc W.","family":"Gerdisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Capps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars G.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.06.014_bb0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fcvm.2018.00046","article-title":"Prosthetic aortic valves: challenges and solutions","volume":"5","author":"Musumeci","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ahj.2020.06.014_bb0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fcvm.2019.00047","article-title":"Bioprosthetic heart valves: upgrading a 50-year old technology","volume":"6","author":"Li","year":"2019","journal-title":"Front Cardiovasc Med."},{"issue":"25","key":"10.1016\/j.ahj.2020.06.014_bb0015","doi-asserted-by":"crossref","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Nishimura","year":"2017","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.ahj.2020.06.014_bb0020","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2020.06.014_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1477-7525-9-91","article-title":"Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study","volume":"9","author":"Almeida Gde","year":"2011","journal-title":"Health Qual Life Outcomes"},{"issue":"23","key":"10.1016\/j.ahj.2020.06.014_bb0030","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.119.041105","article-title":"How did we get here? A historical review and critical analysis of anticoagulation therapy following mechanical valve replacement","volume":"140","author":"MacIsaac","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ahj.2020.06.014_bb0035","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1592\/phco.2005.25.12.1801","article-title":"Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic","volume":"25","author":"Orensky","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.ahj.2020.06.014_bb0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.167.3.229","article-title":"The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study","volume":"167","author":"Kimmel","year":"2007","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.ahj.2020.06.014_bb0045","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.athoracsur.2007.08.071","article-title":"International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement","volume":"85","author":"Eitz","year":"2008","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.ahj.2020.06.014_bb0050","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.thromres.2009.02.012","article-title":"Decreasing warfarin sensitivity during the first three months after heart valve surgery: implications for dosing","volume":"125","author":"Meijer","year":"2010","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.ahj.2020.06.014_bb0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5428\/pcar20130417","article-title":"One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events","volume":"19","author":"Chen","year":"2013","journal-title":"J Manag Care Pharm"},{"issue":"34","key":"10.1016\/j.ahj.2020.06.014_bb0060","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1093\/eurheartj\/ehv580","article-title":"Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years","volume":"37","author":"Glaser","year":"2016","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.ahj.2020.06.014_bb0065","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1056\/NEJMoa1613792","article-title":"Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement","volume":"377","author":"Goldstone","year":"2017","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ahj.2020.06.014_bb0070","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehx141","article-title":"Mechanical versus bioprosthetic aortic valve replacement","volume":"38","author":"Head","year":"2017","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ahj.2020.06.014_bb0075","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.athoracsur.2010.01.046","article-title":"Late outcomes for aortic valve replacement with the Carpentier-Edwards pericardial bioprosthesis: up to 17-year follow-up in 1,000 patients","volume":"89","author":"McClure","year":"2010","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.ahj.2020.06.014_bb0080","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/ejcts\/ezv384","article-title":"Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 50-65 years","volume":"49","author":"Bourguignon","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"issue":"13","key":"10.1016\/j.ahj.2020.06.014_bb0085","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jama.2014.12679","article-title":"Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years","volume":"312","author":"Chiang","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ahj.2020.06.014_bb0090","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jtcvs.2019.02.076","article-title":"Tissue versus mechanical aortic valve replacement in younger patients: a multicenter analysis","volume":"158","author":"Iribarne","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ahj.2020.06.014_bb0095","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2147\/PPA.S152579","article-title":"Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study","volume":"11","author":"Koretsune","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.ahj.2020.06.014_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40271-016-0185-9","article-title":"Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review","volume":"10","author":"Wilke","year":"2017","journal-title":"Patient"},{"issue":"4","key":"10.1016\/j.ahj.2020.06.014_bb0105","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jtcvs.2014.01.004","article-title":"Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial","volume":"147","author":"Puskas","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"24","key":"10.1016\/j.ahj.2020.06.014_bb0110","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.jacc.2018.03.535","article-title":"Anticoagulation and antiplatelet strategies after on-x mechanical aortic valve replacement","volume":"71","author":"Puskas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.ahj.2020.06.014_bb0115","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2020.06.014_bb0120","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ahj.2020.06.014_bb0125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2020.06.014_bb0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.amjcard.2014.11.039","article-title":"A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists","volume":"115","author":"Touma","year":"2015","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2020.06.014_bb0135","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.athoracsur.2014.05.006","article-title":"Clinical evaluation of new heart valve prostheses: update of objective performance criteria","volume":"98","author":"Wu","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.ahj.2020.06.014_bb0140","first-page":"73","article-title":"North American multicenter experience with the On-X prosthetic heart valve","volume":"15","author":"McNicholas","year":"2006","journal-title":"J Heart Valve Dis"},{"issue":"5","key":"10.1016\/j.ahj.2020.06.014_bb0145","first-page":"551","article-title":"Single-center experience with the On-X prosthetic heart valve between 1996 and 2005","volume":"16","author":"Tossios","year":"2007","journal-title":"J Heart Valve Dis"},{"issue":"2","key":"10.1016\/j.ahj.2020.06.014_bb0150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jtcvs.2011.12.059","article-title":"Clinical event rates with the On-X bileaflet mechanical heart valve: a multicenter experience with follow-up to 12 years","volume":"145","author":"Chambers","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ahj.2020.06.014_bb0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"10.1016\/j.ahj.2020.06.014_bb0160","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","article-title":"Apixaban versus warfarin for mechanical heart valve thromboprophylaxis in a swine aortic heterotopic valve model","volume":"37","author":"Lester","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.ahj.2020.06.014_bb0165","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jtcvs.2011.02.011","article-title":"Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves","volume":"141","author":"McKellar","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"16","key":"10.1016\/j.ahj.2020.06.014_bb0170","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320301940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:15Z","timestamp":1762077435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320301940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"alternative-id":["S0002870320301940"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.06.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}